Evidence map›Paper›PMID 41057030›Full record

ReviewSeminars in thrombosis and hemostasis2026

Lipopolysaccharide and Coagulation Factor XII: Biophysics of Contact Activation in Infection.

André L Lira, Katelyn C Drew, Cristina Puy, Joseph J Shatzel, Owen J T McCarty

Abstract readReview
In one paragraph

Review in Seminars in thrombosis and hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

André L LiraDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States.
Katelyn C DrewDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States.
Cristina PuyDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States.
Joseph J ShatzelDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States.
Owen J T McCartyDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, United States.

Funding

Characterization of Coagulation Factor-platelet Interactions: Role of FXIR01HL101972 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Owen J McCarty · 2010 to 2026
$8.5M
Contact Activation and InfectionR01AI157037 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LUPU, FLOREA, MCCARTY, OWEN J · 2020 to 2024
$3.3M
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.R01HL151367 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHATZEL, JOSEPH JAMES · 2020 to 2024
$1.5M
Institute of Allergy and Infectious Diseases R01AI157037National Institutes of Health, National Heart, Lung, and Blood Institute R01HL101972National Institutes of Health, National Heart, Lung, and Blood Institute R01HL144133NHLBI NIH HHS R01 HL101972NHLBI NIH HHS R01 HL151367NIAID NIH HHS R01 AI157037
6 · The paper itself

Abstract

Abstract: Lipopolysaccharide (LPS), a key component of the outer membrane of Gram-negative bacteria, is well-known for its role in triggering inflammation via innate immune receptors. However, evidence suggests that LPS can influence coagulation, in part through activation of the contact pathway. Recent studies from our group and others demonstrate that the supramolecular organization and physicochemical properties of LPS-such as aggregate size, surface charge, and chemotype-critically determine the ability of LPS to activate coagulation factor XII (FXII). While monomeric LPS can modulate FXII activity, only aggregated forms of LPS (e.g., micelles) function as a procoagulant surface, initiating contact activation. This review synthesizes current knowledge on LPS structural heterogeneity and explores how the biophysical properties of LPS govern supramolecular assembly in aqueous environments, ultimately dictating interactions with the contact activation pathway. We further discuss the possible mechanisms by which LPS-driven FXII activation contributes to thromboinflammatory disorders, including disseminated intravascular coagulation and sepsis-associated vascular leakage. Finally, we highlight novel therapeutic strategies-from FXIIa inhibitors to molecules that disrupt LPS supramolecular structures-as potential interventions to mitigate coagulation-driven pathology during bacterial infections. These insights not only reflect our growing understanding of infection-associated thrombosis but may also pave the way for targeted therapies in sepsis and other thromboinflammatory conditions.

Indexed as

Factor XIILipopolysaccharidesAnimalsBlood CoagulationHumansFactor XIILipopolysaccharides

Identifiers

PMID41057030
PMCPMC13616133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.